Upload
others
View
17
Download
0
Embed Size (px)
Citation preview
349
350
REFERENCES
1. Kevin A. Cassady, Helen Yun, Clinical Pathology Made Ridiculously
Simple, 2001
2. P.N. Bennett, M.J. Brown, Clinical Pharmacology, Churchill
Livingstone Publications, 2003.
3. Knox Van Dyke ,Karen Woodfork, Modern Pharmacology and Clinical
Applications, 2002.
4. Goodman & Gilman's The Pharmacological Basis of Therapeutics -
11th Ed. 2006.
5. Greene, W.C., and Peterlin, B.M. Charting HIV's remarkable voyage
through the cell: Basic science as a passport to future therapy. Nature
Med., 2002, 8:673-680. Pubmed
6. Christine M, Pharmacology for the Health Care Professions, 2008.
7. James B. Chin, Control of Communicable Diseases Manual, APHA,
2000.
8. UNAIDS, Report on the Global HIV/AIDS Epidemic. UNAIDS2006
9. Rambaut A, Posada D, Crandall KA, Holmes EC, The causes and
consequences of HIV evolution. Nat. Rev.Genet, 2004, 5, 52–61.
10. 10. Hu W S, Rhodes Q D, V. Pathak, Retroviral recombination: review
of genetic analyses, Front.Biosci, 2003, 8, 143–155
11. Najera R, Delgado E,. Perez A L, Thomson M M, Genetic recombination
and its role in the development of the HIV-1 pandemic, AIDS, 2002,
16:S3-S16.
12. Najera R, Delgado E,. Perez A L, Thomson M M, Genetic recombination and
its role in the development of the HIV-1 pandemic, AIDS, 2002, 16:S3-S16
351
13. Thomson M M, Najera R, Delgado E, Perez A L, Molecular epidemiology of
HIV-1 genetic forms and its significance for vaccine development and
therapy, Lancet Infect. Dis. 2002, 2,461–471
14. Chen LF, Hoy J, Lewin SR Ten years of highly active antiretroviral therapy
for HIV infection. Med. J. Aust. 2007, 186, 146–151
15. Simon V, Ho D D, Abdool K Q, HIV/AIDS epidemiology, pathogenesis
prevention and treatment. Lancet , 2006, 368, 489–504
16. Lassen K, The multi factorial nature of HIV-1 latency, Trends Mol. Med,
2004, 10, 525–531
17. Marcello A L, The hidden HIV-1 challenge. Retrovirology, 2006, 3, 7
18. Richman D D, Antiviral drug resistance. Antiviral Res. 2006, 71, 117–121
19. Xiaoling L, William K C, Transport, metabolism and elimination mechanisms
of anti-HIV agents, Adv. Drug,Del. Rev, 1999, 39, 81.
20. Bruce J A, P-glycoprotein secretory transport, and other barriers to the oral
delivery of anti-HIV drugs, Adv. Drug. Del. Rev., 1999, 39,105
21. Dae D K, Chien Y W, Simultaneous skin permeation of dideoxynucleoside-
type anti-HIV drugs J. Control. Rel, 1996, 40, 67.
22. Dae D K, Chien Y W, Comparison of Skin Permeation of Dideoxynucleoside-
Type Anti-HIV Drugs: Alone Versus Combination, Drug Develop. Ind. Pharm,
1996, 22,1047.
23. Yi J, Toshinobu S, Yasunori M, Kazuhiko J, Effect of Application
Volume of Ethanol-Isopropyl Myristate Mixed Solvent System on
Permeation of Zidovudine and Probenecid Through Rat Skin, Drug
352
Develop Ind. Pharm, 2000, 26, 193.
24. Thomas N S, Panchagnula R, Transdermal delivery of zidovudine:
effect of vehicles on permeation across rat skin and their mechanism
of action Eur. J. Pharm. Sci, 2003, 18, 71.
25. Oussoren C, Magnani M, Fraternale A, Casabianca A, Chiarantini L,
Ingebrigsten R., Underberg W J, Storm G, Liposomes as carriers of the
antiretroviral agent dideoxycytidine-5′-triphosphate Int. J. Pharm, 1999,
180, 261.
26. Duzgunes N, Pretzer E, Simoes S, Slepushkin V, Konopka K, Flasher D ,
Lima M C, Liposome-mediated delivery of antiviral agents to human
immunodeficiency virus-infected cells Mol. Membrane Biol, 1999, 16, 111.
27. Jun Chena, William E. Blevinsb, Haesun Parkc, Kinam Park, Gastric
Retention Properties of Superporous Hydrogel Composites, Journal of
Controlled Release, 64 (2000) 39–51
28. Feleke F, Aendale T , Gebre C, Oral floating extended release
stavudine hydrophilic matrix tablets: formulation design and in vitro
investigations, Ethiopian Pharmaceutical Journal , 2007, 25 , 51-62.
29. Robert D, Denise M J, Sustained release beadlets containing stavudine, US
patent 7135465, 2001.
30. Sahoo S, Mallick A A, Barik B B, Senapathi P C, Formulation and in vitro
Evaluation of Eudragit Microspheres of Stavudine, Tropical Journal of
Pharmaceutical Research, 2005, 4, 369-375,
31. Sureshwar P, Poly (lactide-co-glycolide) microspheres of stavudine were
prepared by the solvent evaporation technique, IPC 2008
32. U.S. Department of Health and Human Services, Food and Drug
Administration,Center for Drug Evaluation and Research (CDER),
353
Drugs@FDA, Zerit XR, stavudine,label, 2008
33. Ravi P R, Ganga S, Saha R N, Design and Study of Lamivudine Oral
Controlled Release Tablets, AAPS PharmSciTech, 2007, 8 , 167-175,.
34. Himadri sen, Surva Kumar J, inventors. Long acting composition containing
zidovudine and Lamivudine. US patent publication US 20050175694A1.
August 11, 2005.
35. Amitava Ghosh, Udaya Kumar Nayak, Partha Roy, Development, evaluation
and method selection for the preparation of lamivudine microspheres,
Pharmacy on-line, 2007.
36. Prathiba V , Bharathi A, Formulation & evaluation of lamivudine
microspheres, Pharmabiz, August 2008.
37. Ingunn Tho , Bernd Liepold, Joerg Rosenberg, Markus Maegerlein, Martin Brandl and Gert Fricker
Formation of nano/micro-dispersions with improved dissolution
properties upon dispersion of ritonavir melt extrudate in aqueous
media‖ EuropeanJournalofPharmaceuticalSciences Volume 40, Issue
1, 16 April 2010, Pages 25-32.
38. Manuela Ehrhardt0, Marion Möck, Walter E. Haefeli, Gerd Mikus and
Jürgen Burhenne ―Monitoring of lopinavir and ritonavir in peripheral
blood mononuclear cells, plasma, and ultrafiltrate using a selective
and highly sensitive LC/MS/MS assay‖ JournalofChromatograph
Volume 850, Issues 1-2, 1 May 2007, Pages 249-258.
39. John Ray, Edna Pang and Dianne Carey ―Simultaneous determination
of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by
high-performance liquid chromatography‖ JournalofChromatography
Volume 775, Issue 2, 5 August 2002, Pages 225-230.
40. Eliane Maria Donato, Laura Alegria Martins, Pedro Eduardo Fröehlich,
354
and Ana Maria Bergold Development and validation of dissolution test
for lopinavir, a poorly water-soluble drug, in soft gel capsules, based
on in vivo data‖ JournalofPharmaceuticalandBiomedicalAnalysis
Volume 47, Issue 3, 15 July 2008, Pages 547-552 .
41. Yan Shen 1 and Jiasheng Tu Preparaed and evaluated the Ocular
Pharmacokinetics of Ganciclovir Liposomes. Int. J. Pharm., 2008,
195(1-2), 125-135.
42. Rahman Z, Ali M, Khar RK. Design and evaluation of bilayer floating
tablets of captopril. Acta Pharm.2006; 56: 49-57.
43. Xiaoqiang Xu, Minije S, Feng Z, Yiqiao Hu. Floating matrix dosage
form for phenoporlamine hydrochloride based on gas forming agent: In
vitro and in vivo evaluation in healthy volunteers. Int J Pharm. 2006;
310:139-145.
44. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of
cimetidine: formulation, characterization and in vitro evaluation. Acta.
Pharm. 2005; 55: 277-285.
45. Jain SK, Awasthi AM, Jain NK, Agarwal GP. Calcium silicate based
microspheres of repaglinide for gastroretentive floating drug delivery:
preparation and in vitro characterization. J. Control. Release. 2005;
107: 300-309.
46. El-Kamel AH, Sokar MS, AlGamal SS, Naggar VF. Preparation and
evaluation of ketoprofen floating oral drug delivery system. Int. J.
Pharm. 2001; 220:13-21.
47. Mine O., Evren H, G., Gokhan E., 2006 Release and diffusional
modeling of metronidazole matrices.Eur.J.Pharm.Biopharm.,63, 331-
339.
48. Feng-Quian L., et al., 2006, In-vitro controlled release of sodium
ferulate from compritol 888 ATO- based matrix tablets.Int J
355
.Pharm.,324, 152-157.
49. Testuo H., et al., 2005. Formulation study and drug release
mechanism of a new theophylline sustained release prepration. Int. J.
Pharm., 304, 91-101.
50. Yu-E-Zhang, Joseph B.S., 2003. Melt granulation and heat treatment
for wax matrix-controlled release. Drug. dev. Ind. Pharm., 29(2), 131-
138.
51. Aiman A.O2001.controlled release of Tramadol hydrochloride from
matrices prepared using glyceryl Behenate. Eur. j. pharm. Biopharm.,
52, 231-235.
52. Alan, 1996.alternative granulation technique: Melt granulation. Drug.
Dev. ind. pharm., 29(9), 917-924.
53. Parish, Edward J.; Terrence L. Boos; Shengrong Li (2002). "The
Chemistry of Waxes and Sterols". in Casimir C. Akoh, David B. Min..
Food lipids: chemistry, nutrition, and biochemistry (2nd ed.). New
York: M. Dekker. p. 103. ISBN 0824707494.
54. Dave BS, Amin AF, Patel MM. Gastroretentive Drug Delivery System of
Ranitidine hydrochloride: formulation and invitro evaluation. AAPS
Pharm. Sci. Tech. 2004; 5(2): article 34.
55. Yang, L., Esharghi, J., Fassihi, R., ―A new intra gastric delivery system
for the treatment of helicobacter pylori associated gastric ulcers: in
vitro evaluation‖, J Control. Rel., 1999, 57(3), 215-222.
56. Wu, W., Zhou, Q., Zhang, H.B., Ma, G.D., Fu, C.D., ―Studies on
nimodipine sustained release tablet capable of floating on gastric
fluids with prolonged gastric resident time‖, Yao. Xue. Xue. Bao.,
1997, 32 (10), 786-790.
57. Xiaoqiang, X., Minjie, S., Feng, Z., Yiqiao, H., ―Floating matrix dosage
356
form for phenoporlamine hydrochloride based on gas forming agent: In
vitro and in vivo evaluation in healthy volunteers‖, Int. J. Pharm.,
2006, 310(1-2), 139-145.
58. Shoufeng L, Senshang L, Chein YW,Daggy BP, Mirchandani HL.
Statisticaloptimization of gastric gloating systemfor oral controlled
delivery of calcium.AAPS Pharm. Sci. Tech. 2001; 2: 1‐12.
59. Deshpande AA, Shah NH, Rhodes CT,Malick W. Development of a
novelcontrolled release system for gastricretention. Pharm. Res. 1997;
14(6):815‐819.
60. Margret chandira, debjit bhowmik, chiranjib, b. jayakar formulation
and evaluation of gastroretentive drug deliverysystem of
gastroprokinetic drug itopride hydrochloride International Journal of
Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010.
61. El‐Kamel, Sokas MS, Algamal SS.Preparation and evaluation
ofKetoprofen floating oral delivery system. Int. J. Pharm. 2001; 220 :
13‐21.
62. Chinam niranjan patra et al, Design and evaluation of sustained
release bilayer tablets of propranolol hydrochloride Acta Pharm. 57
(2007) 479–48910.2478/v10007-007-0038-0.
63. Eunice K K, Cristina H R, Eunice E M, Simone S A, Valentina P,
Determination of lamivudine in human plasma by HPLC and its use in
bioequivalence studies, International Journal of Pharmaceutics 2005, 297,
73–79.
64. Namita K, Sateesh K, Ramesh P, Simultaneous determination of lamivudine
and stavudine in antiretroviral fixed dose combinations by first derivative
spectrophotometry and high performance liquid chromatography, Journal of
Pharmaceutical and Biomedical Analysis 2006, 41, 761–765.
357
65. Bin Fan, James T. Stewart, Determination of zidovudine
/lamivudine/nevirapine in human plasma using ion-pair HPLC, Journal of
Pharmaceutical and Biomedical Analysis 2002, 28 , 903–908.
66. Emilia Marchei , Luisa Valvo , Roberta Pacifici, Manuela Pellegrini ,Gianna
Tossini , Piergiorgio Zuccaro , Simultaneous determination of zidovudine and
nevirapine in human plasma by RP-LC, Journal of Pharmaceutical and
Biomedical Analysis, 2002, 29 ,1081–1088.
67. Ashenafi Dunge, Nishi Sharda, Baljinder Singh, Saranjit Singh, Validated
specific HPLC method for determination of zidovudine during stability
studies, Journal of Pharmaceutical and Biomedical Analysis ,2005, 37 ()
1109–1114.
68. C. M. Phechkrajang, E.E. Thin, L. Sratthaphut, D. Nacapricha and P.
Wilairat ―Quantitative Determination of Lopinavir and Ritonavir in
Syrup Preparation by Liquid Chromatography‖ Mahidol University
Journal of Pharmaceutical Science 2009; 36 (1-4), 1-12.
69. Usami Y, Oki T, Nakai M, Sagisaka M, Kaneda T. ―A simple HPLC
method for simultaneous determination of lopinavir, ritonavir and
efavirenz‖ Chem Pharm Bull (Tokyo). 2003 Jun; 51(6):715-8.
70. U.S. Department of Health and Human Services, Food and Drug
Administration,Center for Drug Evaluation and Research (CDER),
Drugs@FDA, Retrovir, zidovudine, Label information, 2007.
71. U.S. Department of Health and Human Services, Food and Drug
administration,Center for Drug Evaluation and Research (CDER),
Drugs@FDA, Epivir, lamivudine, Label information, 2008.
72. U.S. Department of Health and Human Services, Food and Drug
Administration,Center for Drug Evaluation and Research (CDER),
Drugs@FDA, Retrovir, zidovudine, Label information, 2009.
358
73. U.S. Department of Health and Human Services, Food and Drug
Administration,Center for Drug Evaluation and Research (CDER),
Drugs@FDA, Retrovir, zidovudine, Label information, 2009.
74. U.S. Department of Health and Human Services, Food and Drug
Administration,Center for Drug Evaluation and Research (CDER),
Drugs@FDA, Retrovir, zidovudine, Label information, 2010.
75. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 556-561.
76. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 286-288.
77. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 293-294.
78. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 762-763.
79. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 542-549.
80. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 772-774.
81. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 290-293.
82. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 554-556.
83. http://www.gattefosse.com/media/document/tds_sedefos_75.pdf,
Pg-1-3.
84. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 517-522.
359
85. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 525-533.
86. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 317-325.
87. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 317-325.
88. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 317-325.
89. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg517-520.
90. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg517-520.
91. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg110-114.
92. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 622-624.
93. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 404-408.
94. Handbook of pharmaceutical excipients‖, 6th edition, Raymaond C Row
Pharmaceutical Press, London, 2009. Pg 129-131.
95. Hilton Ak, Deasy PB. In vitro and in vivo evaluation of an oral
sustained release floating dosage form of amoxicillin trihydrate. Int. J.
Pharm. 1992; 86:79-88.
96. Shyam Shimpi, Bhaskar Chauhan, K. R. Mahadik, and Anant
Paradkar. Preparation and Evaluation of Diltiazem Hydrochloride-
Gelucire 43/01 Floating Granules Prepared by Melt Granulation. AAPS
360
PharmSciTech 2004; 5 (3).
97. Bhaskar Chauhan, Shyam shimpi, K.R. Mahadik. Preparation and
Evaluation of Floating Risedronate Sodium-Gelucire 43/01
Formulations. Drug. Dev -Ind-Pharm31: 851-860, 2005.
98. Arthur H K, Hand book of pharmaceutical excepients, 3 rd ed,
American pharmaceutical association, Washington DC, 2000,
Appendix II, 642.
99. Shyam shimpi, K.R. Mahadik. Drug. Dev -Ind-Pharm31: 701-10,
2004.
100 S. J. Hwang, H. Park, K.Park,―Gastric retentive drug delivery systems.‖
Crit. Rev. Ther. Drug Carrier Syst., 1998.15, 243–284.
101. ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and
Products, http://www.emea.europa.eu
102. Lazarus, J. and Cooper, J., J. Pharm. Sci., 50, 715, 1961.
103. Wagner, J.G., J. Pharm. Sci., 58, 1253, 1969.
104. Higuchi, T., J. Pharm. Sci., 52, 1145, 1963.
105. Korsemeyer, E. W., Gurny, R., Doelker, E.M., Buri, p. and Peppas,
N.A., Int, J. Pharm., 21, 25, 1983.
106. Ritger, P.L and Peppas, N.A., J. Control. Release, 5, 37, 1987.
107. Food & Drug Administration, SUPAC-IR Questions and Answers.
Center for Drug Evaluation and Research, 1995.
108. Food & Drug Administration, Guidance for Industry: Dissolution
Testing of Immediate Release Solid Dosage Forms. Center for Drug
Evaluation and Research, 1997.
109. Food & Drug Administration (a) In: Guidance for Industry: Immediate
361
Release Solid Dosage Forms: Scale-up and Post Approval Changes
(SUPAC-IR): Chemistry, Manufacturing and Controls, In Vitro
Dissolution Testing and In Vivo Bioequivalence Documentation. Center
for Drug Evaluation and Research, 1995.
110. Bhaskar Chauhan, Shyam shimpi, K.R. Mahadik. Preparation and
Evaluation of Floating Risedronate Sodium-Gelucire 43/01
Formulations. Drug. Dev -Ind-Pharm31: 851-860, 2005.
111. Shyam Shimpi, Bhaskar Chauhan, K. R. Mahadik, and Anant
Paradkar. Preparation and Evaluation of Diltiazem Hydrochloride-
Gelucire 43/01 Floating Granules Prepared by Melt Granulation. AAPS
PharmSciTech 2004; 5 (3).
112. Basak SC, NagashwaraRao K, Manavalan R,RamaRao P. Indian
J..Pharm. Sci. 2006; 66(3): 313-316.
113. Talukder R, Fassihi R, Jain NK. A new approach in gastro retentive
delivery systems Drug. Dev -Ind-Pharm; 30(4): 405-412.
114. Arthur H K, Hand book of pharmaceutical excepients, 3 rd ed,
American pharmaceutical association, Washington DC, 2000,
Appendix II, 642.
115. Food & Drug Administration, SUPAC-IR Questions and
Answers.Center for Drug Evaluation and Research, 1995.
116. Shyam Shimpi, Bhaskar Chauhan, K. R. Mahadik, and Anant
Paradkar. Preparation and Evaluation of Diltiazem Hydrochloride-
Gelucire 43/01 Floating Granules Prepared by Melt Granulation. AAPS
PharmSciTech 2004; 5 (3).
117. ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and
Products, http://www.emea.europa.eu.
118. Food & Drug Administration, Guidance for Industry: Dissolution
362
Testing of Immediate Release Solid Dosage Forms. Center for Drug
Evaluation and Research,1997
119. Food & Drug Administration, Guidance for Industry: Immediate
Release Solid Dosage Forms: Scale-up and Post Approval Changes
(SUPAC-IR): Chemistry, Manufacturing and Controls, In Vitro
Dissolution Testing and In Vivo Bioequivalence Documentation. Center
for Drug Evaluation and Research. 1995.
120. Ansal H C, Popovich N G, Allen L V. Jr. Pharmaceutical Dosage forms
and Drug Delivery Systems, , B.I Waverly, 6 th Ed ,
Newdelhi,1999,61.
121. Cuny L D, Huwyler J, Wiese M, Kansy M, Computational aqueous
solubility prediction for drug-like compounds in congeneric series
European Journal of Medicinal Chemistry, 2008, 43, 501.
122. Lipinski C A, Lombardo F, Dominy B W, Feeney PJ, Experimental and
computational approaches to estimate solubility and permeability in
drug discovery and development settings, Adv. Drug Delivery. Reviews,
2001, 46, 3.
123. S K Sahoo, Abdul A M, BB Barik, Prakash , Formulation and in vitro
Evaluation of Eudragit Microspheres of Stavudine, Tropical Journal of
Pharmaceutical Research, 2005; 4 , 369-375.
124. Punna R Ri, Sindhura G, and Ranendra N S, Design and Study of
Lamivudine Oral Controlled Release Tablets, AAPS PharmSciTech,
2007, 8, 4.
125. D.Varun, Bahul Z Awen, Ch. Babu Rao, K.Mukkanti and P.Nagaraju,
A Validated Reverse Phase HPLC method for the Simultaneous
Estimation of Ritonavir and Lopinavir in Pharmaceutical Dosage
Forms, Asian J. Research Chem. 3(3): July- Sept. 2010, 805-808.
363
126. Varun Dasari, Babu Rao Chandu, Mukkanti Khagga, Sumalatha
Gindi, New Simple UV Spectrophotometric Method For the Estimation
of Valganciclovir In Bulk And Its Formulation, Pharmanest, An
International Journal of Advances in Pharmaceutical Sciences, 2010,
Nov-Dec, 1(2), 282-286.
127. V.Lannuccelli, G.Coppi, R. Sansone And G. Ferolla, Air Compartment
Multiunit System For Prolonged Gastric Residence, part II- In vivo
Evaluation, Int.J. Pharma, 1982, 174 (1-2), 55-62.
128. I.R. Wiliding and S.P. Newmman, Ginving Decissions More Precious In
Drug Development, Use of Radionuclide Imaging, Drug. Dev. Syst. &
Scie, 2001, 1(1), 5-10.
129. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery
system: A Review, Int. J. Pharm. Res. CODEN (USA): IJPRIF ISSN:
0974‐4304.2009; 3:623‐633.